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Abstract. When building simulations of complex systems the
task of validation is often overlooked. Validation helps provide
confidence in the simulation by exploring the link between the
models that we build and the real complex system. We inves-
tigate software engineering validation techniques from outside
the area of complex systems to assess their applicability for the
types of simulation we build. We then provide an example of
how such techniques can be applied to a complex systems sim-
ulation of cells migrating from blood vessels into lymph nodes
through the walls of the blood vessels. We suggest that explic-
itly stating the modelling and simulation assumptions we make
is key to the process of validation. Concluding, we highlight a
possible process for validating complex systems that explicitly
incorporates environmental aspects.
Keywords: complex systems, simulation, modelling, val-
idation
1 Introduction
Simulations are used to model complex systems such as biological phe-
nomena, economies and human societies, for use in research investigation
in vivo, in vitro and in silico. These systems are complex in the sense
of having elaborate behaviour at a high level that is the consequence of
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many simple behaviours at a lower level. The high-level behaviour can-
not be deduced as a simple combination of low-level behaviours. Space,
time and the environmental context are critical features.
In this paper, we present an initial engineering exploration in to the
validity of a complex system simulation of part of the immune system,
based on collaborative work with the York Centre for Immunology and
Infection (CII), undertaken as part of the CoSMoS project5. We focus
on a part of the conceptual model, and consider how, and to what ex-
tent, it is possible to validate this against the biological evidence of in
vivo experiments. Our modelling assumptions, and validation problems,
bring into consideration the importance of local environmental factors in
modelling such complex systems. The analysis also highlights the limits
of biological imaging based technologies that cannot provide dynamic
insight in to the key features of the system; this in turn highlights areas
where the biological research could focus.
Section 2 presents a review of simulation and its use in scientific re-
search. The following section summarises biological research on the mi-
gration of lymphocytes to lymph nodes. We then explore the engineering
validation of our simulation. Finally, in section 6, we propose an exten-
sion of Sargent’s simulation process to express some of the complications
of complex-systems modelling and simulation engineering.
2 Computer simulation: science and engineering
Computer simulation has been used to explore biological systems for
many years. Traditional simulations generate output from equations (dif-
ferential equations, Markovian models, etc.) that have been developed to
mirror trends or behaviour in, for instance, biological populations. More
recently, computer simulation has been used to model the possible effects
(co-ordinated or emergent) of biological components or organisms acting
in their environment. Essentially, simulations have two purposes: some
are built in co-operation with research scientists in an effort to improve
scientific understanding of natural systems; others are built as artificial
systems to construct and explore alternative realities (either as science
fiction or visions for future engineering). Here, we focus on a case study
whose purpose is to contribute to scientific understanding in immunology
permitting simulation of events that are difficult to experimentally vali-
date in vivo. The aim is to produce a simulation in which the biologist
has confidence and can help direct their wetlab experimental research.
5 The CoSMoS project, EPSRC grants EP/E053505/1 and EP/E049419/1,
http://www.cosmos-research.org/, is building capacity in generic modelling
tools and simulation techniques for complex systems.
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Computer simulation of biological phenomena is important because
static models cannot capture the dynamic features that characterise the
behaviour of complex systems. For example, systems biologists are in-
creasingly adopting conventional software engineering design diagrams
to express static structures, and patterns of interaction in their models;
these modelling approaches cannot express time, space or the the fea-
tures and consequences of large numbers of interacting instances [24].
Time and space (or at least spatial orgainisation) are essential to com-
plex systems behaviour. A key aspect of space, which is also outside
the remit of conventional modelling, is environmental interaction – both
among components, and of components with their local environment:
the behaviour of a complex system depends critically on the way that
the (collective) components interact with their environment over time;
failure to adequately model the environmental context naturally leads
to non-realistic models of the complex system.
Thus, a scientifically-valid simulation has to extract suitable envi-
ronmental aspects, at an appropriate level of abstraction; it also has
to provide evidence that its environmental representation, as well as its
scientific model, are adequate abstractions from the biological reality.
Despite the importance of realistic abstraction, the validity of com-
puter simulations has not been a significant concern of simulators, except
in the critical systems context. Typically, a simulation is judged by its
ability to produce something like the expected results by a process that
looks a bit like reality, and there is little concern for the quality or sci-
entific relevance of the underlying simulation [11]. Simulations can be
misleading, for instance because the output captures artefacts of the
simulation software rather than patterns of behaviour, or where the at-
tempt to approximate reality results in simulations whose complexity is
as impenetrable as that of the observed system.
Scientific validity, like engineering validity, means that it must be
possible to demonstrate, with evidence, how models express the scientific
realities. Validity implies both adequate abstraction, and adequate de-
velopment processes. Many computer simulations are poorly engineered:
there is little attempt to record design of components or of the envi-
ronmental context used in the simulation system. Assumptions and gen-
eralisations are not documented, and are thus not exposed to scientific
scrutiny. An immediate result of this focus is a long-running intellectual
debate about whether it is possible to do science through simulation
(see [19, 22, 36, 5]). Bullock (in [36]) observes that, to assess the role
and value of complex systems simulation, we need to address deep ques-
tions of comparability: we need a record of experience, of how good
solutions are designed, of how to chose parameters and calibrate agents,
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and, above all, how to validate a complex system simulation. To address
these problems, we need principled approaches to the development of
computer simulations.
For inspiration in engineering scientifically-valid simulations, we turn
to two areas: non-complex critical systems, and agent modelling. Com-
puter simulation of non-complex (but nevertheless complicated) systems
has a long history, and the need to assure high-integrity and critical-
systems models has led to a corpus of work on developing, verifying and
validating simulation models. In intelligent agent modelling, there are
methods for systems development that focus attention on the different
aspects that need to be considered; some agent work has been taken
forward for use in complex critical systems at the social, or macro, scale.
2.1 The process of simulation development
In high-integrity systems engineering, the foundations of a simulation
process date from the late 1970s. For instance, Sargent (e.g. [28, 30])
presents a process (figure 1) that starts with a problem entity, or de-
scription of the phenomenon to be modelled. From the problem entity,
a conceptual model is developed in a suitable representation – Sargent
reviews diagrammatic models [29], and also notes mathematical or logi-
cal modelling paradigms [30]. Finally, a computerised model implements
the conceptual model.
The simulation process is an iterative cycle, which includes an ex-
perimentation link between the problem entity and the computerised
model. This allows the developers to trial-and-error simulation elements
and settings, and to compare the results to the problem entity.
The second notable aspect of the simulation process is the explicit
inclusion of verification (in the software engineering of the computerised
model) and validation – both of models against reality, and of the data
used to test the conceptual and computerised models. We return to this
aspect in the next section.
The simulation process has much in common with conventional soft-
ware engineering lifecycles – it presents a high-level summary of the nec-
essary attributes of a development, rather than a comprehensive guide
to achieving a high-quality engineered product. This area is addressed
to some extent in agent-oriented modelling.
Sudeikat et al [33] give an insightful review of multi-agent system
development methods, which, like Sargent, focuses on matching meth-
ods to the requirements of specific simulation targets. They identify as
the foci of current methods: internal architecture, social architecture,
communication, autonomy, pro-activity and distribution. Some of the re-





















Fig. 1. Sargent’s model of the simulation development process [28]
viewed methods are sophisticated software-engineering approaches, such
as Prometheus [21] (figure 2).
These methods provide an integration layer for the styles of model
(usually diagrams) that are needed to express the static structures and
interactions of the overall conceptual model. Implementation is often well
researched, with platforms, patterns, and workbenches (see, for instance,
the ACE resources, www.econ.iastate.edu/tesfatsi/ace.htm). Agent mod-
elling methods are used in robotics, social agent systems, and similar
areas, but are also entering high-integrity systems engineering: for in-
stance, Alexander [1] uses Prometheus in the simulation of command-
and-control systems. Critical systems use means that some work exists
on adding validation activities to the modelling activities covered in the
original methods.
Two immediate issues arise with the agent modelling methods. The
first is that they are oriented to social systems – including human-scale
high-integrity systems. This means that the technical emphases are on
capturing the autonomy or design for learning – the BDI (beliefs-desires-
intentions [12]) of agents. The second issue is that these methods do not
capture the time, space, and component-quantity aspects of complex sys-
tems, or the layered abstraction aspect, noted above. The representation
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Fig. 2. The Prometheus development method [21]
of these key features are left to the inspiration of the implementer, and
are thus hidden from validation scrutiny.
2.2 Verification and validation of simulations
There is a significant corpus of work from outside the area of complex sys-
tems on validating and verifying simulation models. However, although
this work proffers general reminders, its direct advice is difficult to adapt
to complex system simulation. Zeigler [39] presents a theory for modelling
and validation of simulations; his theory is predicated on the fact of a ho-
momorphism between conceptual models and simulations, and does not
provide obvious pointers as to how the homomorphism is established –
that is, verification of the development process is assumed.
Similar validation concepts come from Sargent, elaborating the val-
idation aspects of the simulation process (figure 1, above). Sargent [30]
reminds us that a model should be developed for a specific purpose... and
its validity determined with respect to that purpose. Furthermore, Sargent
notes that the level of assurance needed depends on the purpose of the
simulation, and should be set independently of the development of the
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Technique Comments on Sargent’s suggestions
Animation, operational
graphics
Specifically, graphical visualisation, either of sys-
tem behaviour or of operational parameters






Typical domain-style testing of behaviour under
normal and extreme input and operating condi-
tions
Event validity Compare the events in real and simulated sys-
tems
Face validity (ask a domain
expert), traces
Appeal to logic or to domain experts to check the
validity of model components or data
Historical data validation,
predictive validation
Either drive a simulation with historical data and
compare results to reality; or drive a simulation




Three historical approaches can be combined to
develop based on sound theory and assumptions,
with empirical validity checks where possible.
Rationalism The veracity of assumptions is rationally justifi-
able, and valid models arise from valid assump-
tions
Empiricism All assumptions and outcomes are empirically
validated
Positive economics The model can predict the future, so causal rela-
tionships and mechanisms are of no concern
Internal validity Used on stochastic models; comparison of consis-
tency of results across runs
Turing tests Can an expert tell that it is not the real system?
Table 1. Validation techniques for simulation development (based on descrip-
tions from [30])
simulation – good software engineering practice. Sargent’s development
process (lifecycle) for simulations explicitly incorporates verification and
validation activities, and he proposes a range of approaches to validation,
summarised in table 1.
Clearly, some of Sargent’s suggestions are inappropriate for com-
plex systems work: if we knew the workings of the complex system well
enough to understand event validity and traces, we would not need a
computer simulation for research purposes. However, wherever such in-
ternal analyses are possible, they should be conducted. We need to be
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confident that computer simulations accurately replicate contributory
non-complex features. Comparison with real systems is essential, but is
potentially dangerous – variants on predictive validation can lead to (ac-
cidental) construction of simulations that are self-fulfilling prophesies,
whilst historical data validation tends to pick only the data that best
match the simulation.
Perhaps the most useful of Sargent’s suggestions relate to analysis
of assumptions – though situating this in historical theories of ratio-
nalism and empiricism tends to mask their value. A common (possibly
universal) failing of research simulations is the failure to document the
assumptions that they make, both about the science that underpins the
models, and about the means used to create the simulation. We will
return to assumptions in the case study, below.
2.3 Other computer simulations for biological research
There are a number of current interdisciplinary research projects that
use aspects of software engineering to produce high-quality computer
simulations to support biological research.
PEPA [6, 7] is typical of several approaches that use stochastic pro-
cess algebra to construct models of cell signal transduction pathways. In
PEPA, complementary models are developed of a reagent view and a net-
work view. The models are proven isomorphic with each other, and iso-
morphic with conventional differential equation models of transduction.
Verification (that the implementation captures the conceptual model)
is formal and explicit, and the ability to mimic the analytical models
that the biologists create contributes to the validation of the conceptual
model against the reality. This is akin to Sargent’s comparison to other
models technique, although, in common with other differential equations,
the validity of the analytical models is difficult to show.
Reactive Animation (RA) [10, 9, 14] is another robustly-engineered
research simulation; it uses Rhapsody statecharts (state machines) and
Live Sequence Charts (connectivity diagrams), plus data from biologi-
cal experimentation, to drive powerful biological visualisations (for in-
stance, of T cell activity in the thymus). RA reverse engineers biological
systems, using a well-understood software engineering analogy [27]. RA
thus exemplifies a number of Sargent’s comparatively-based validation
techniques, as well as quality software engineering design and verifica-
tion. In both PEPA and RA, high-quality computer engineering and
attention to validation produces simulations that biologists can rely on
to direct their research.
Whilst these initiatives are both scientifically and computationally
successful, they are not easily generalisable. The specialised components
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(such as process algebras) and proprietary tools (such as Rhapsody state
charts) tie the initiatives closely to the groups that own them. This
makes it hard to do a comprehensive evaluation of PEPA or RA as
candidate for a general complex system development process – in other
words, it is hard to generalise from these otherwise excellent initiatives
in biologically-driven computer simulation.
In our work, we take inspiration from Sargent’s process and RA mod-
elling. Our conceptual model is a very simple form of state machine, to
express the possible states of a lymphocyte. Like conventional agent
modelling, much of the environmental context is captured between the
conceptual model and the implementation. However, we then apply Sar-
gent’s validations, and a deviational approach to assumption generation
by providing evidence for arguments (based on work by Pumfrey [25],
Srivatankul [31], Allenby [2] and others applying deviational analyses to
safety or security assurance work). This approaches to engineering as-
surance not only reveals limitations (and strengths) of our simulation,
but can also be used to explore the effect of limitations of the biological
knowledge of the system.
The following section provides biological background on the case
study. We then review our simulations, and discuss connotations of our
findings for complex systems modelling.
3 Migration of lymphocytes in the lymph node
3.1 Lymph Nodes
The mammalian immune system possesses many specialised cells that are
collectively known as the leukocytes or white blood cells. The leukocytes
can be divided into a number of distinct groups with different function-
alities. One such group is the lymphocytes, which are vital to recognising
and mounting an immune response to various harmful pathogens such
as bacteria and viruses. The lymphocytes can be further classified into
two distinct populations of cells: B cells and T cells. As well as spe-
cialised cells, the mammalian immune system also comprises a number
of immune organs. One such organ is the lymph node, which is a small
(about the size of a pea in humans) bean-shaped immune organ (figure
3) rich in lymphocytes and other leukocytes, providing a place where im-
mune response to pathogens in the lymph may be triggered and develop.
The structure of the lymph node is made up of a number of specialised
areas supporting different cellular environments. There are hundreds of
lymph nodes in various locations around the body.
Bodily fluid known as lymph drains into lymph node through a num-
ber of afferent lymph vessels connected to the lymphatic system; lymph
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Fig. 3. Structure of a lymph node from [16]
leaves the lymph node through a single efferent lymph vessel. Lymph
contains many different leukocytes, proteins and other particles (possibly
pathogenic) that have drained from the peripheral parts of the body. The
lymph node is also connected to the circulatory system via a lymphatic
artery and vein. It is through the lymphatic artery that lymphocytes en-
ter the lymph node. Lymphocytes can then migrate through specialised
blood vessels (via a mechanism described below) into the functional tis-
sue of the lymph node. Once there, lymphocytes can interact with other
leukocytes that have encountered pathogens and entered the lymph node
from the lymph, to initiate an appropriate immune response.
3.2 Endothelial Cells, Pericytes and High Endothelial
Venules
Figure 4 summarises the main types of blood vessel present in the body:
arteries are the large vessels that carry oxygenated blood from the heart;
arterioles branch off the arteries carrying blood to the capillaries; capil-
laries are the smallest blood vessels in the body and allow the interchange
of components between the blood and body tissues; venules carry the de-
oxygenated blood from capillaries; and veins then carry de-oxygenated
blood back to the heart.
The internal surface of all blood vessels is made up of endothelial
cells. In the lymph node, a minority of the venules have plump (high)
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Fig. 4. The relationship between the different types of blood vessel from
http://training.seer.cancer.gov/module anatomy/images/illu capillary.jpg
Fig. 5. A comparison of a normal venule with a lymph node HEV from [20].
In the HEV, the ring of endothelial cells are much larger.
endothelial cells that have a significantly larger diameter than normal
endothelial cells. These venules are called the high endothelial venules
(HEVs) [15] (see figure 5). Areas of HEVs occur in the lymph node at
various points (figure 6).
It is in HEVs that lymphocytes can migrate from the blood though
the endothelial cells into the functional tissue of the lymph node. Only
lymphocytes can interact with and cross HEVs, other leukocytes are ex-
cluded [20]. It is estimated that a quarter of the circulating lymphocytes
migrate from the blood after entering an HEV [13].
HEVs (and other small blood vessels) are surrounded by pericytes,
shown in figure 7. They are a form of vascular smooth muscle cell sur-
rounding endothelial cells that are responsible for constriction and dila-
tion of blood vessels. This regulates blood flow and diameter of the HEV,
and thus affects the ability of lymphocytes to migrate [26]. A large influx
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Fig. 6. The flow of cells in and out of a lymph node from [20]. Lymphocytes
and dendritic cells enter the lymph node by two routes. Most dendritic cells
enter though afferent lymph, settling near HEVs in paracortex (due both to
lymph node structure and local production of chemokines). Most lymphocytes
enter the lymph node across HEVs.
Fig. 7. Cross-section of a capillary from [4]. EC = endothelial cell, PC =
pericyte, vSMC = vascular smooth muscle cell.
of lymphocytes into the lymph node during an immune response causes
it to visibly swell. This is know as lymph node hypertrophy.
3.3 Lymphocyte Rolling and Migration in the HEV
All leukocytes are able to migrate through blood capillaries via the same
mechanism. Only lymphocytes, however, can migrate through the spe-
cialised HEV in a lymph node. The process of migration is due to an
adhesion cascade of various cell surface receptors and molecules. Origi-
nally identified as a three-step process of rolling, activation and arrest,
the migration process has now been augmented, as shown in figure 8.
Each step is initiated and regulated by specific signalling molecules and
receptors [18].
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Fig. 8. The leukocyte adhesion cascade from [18]. The three historical steps
are shown in bold.
Fig. 9. Migration of T-cells across HEVs from [16]
To migrate, a leukocyte must pass through endothelial cells, the
endothelial-cell basement membrane and pericytes. Migration through
endothelial cells can be rapid (2-5 minutes), whilst penetrating base-
ment membrane takes longer (5-15 minutes) [18].
Migration of lymphocytes from HEVs is controlled by a specific ar-
ray of adhesion molecules that facilitates lymphocyte migration but bars
other leukocytes (figure 9). Chemokines (chemical signalling molecules)
that are produced by or adherent to HEVs are important in the control
of lymphocyte migration, however, the precise mechanisms by which
chemokines work in vivo are unclear [16]. Several chemokines are prob-
ably required for the movement of lymphocytes through HEV, but how
many and in what order is unclear [20].
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4 Developing a lymphocyte migration simulation
In section 2.2 we highlighted the importance of explicitly stating the
purpose of a simulation as it will directly influence the design decisions
and assumptions we make. Our aim is to model the migration of lympho-
cytes through the high endothelial venules (HEV) of the lymph nodes,
and construct computer simulations of the lymphocytes as a complex
system. Using these simulations we can investigate possible factors that
lead to the observed lymph node hypertrophy during infection. We are
interested in how the number of migrating lymphocytes changes under
different conditions, thus the desired output of any simulation will be
numerical data detailing lymphocyte migration rates. The simulations
should enable us to test hypotheses such as the increase in lymphocytes
in the lymph node during infection is due to dilation of the high endothe-
lial venules.
In this section, we outline the processes that we use to develop the
simulations; in the section 5 we turn to validation. Following Sargent’s
process, figure 1, the biological literature summarised above provides the
starting context for our case study, the problem entity. Our conceptual
model is first described followed by our computerised model or simula-
tions. To aid the analysis of our modelling and simulation process, we
have laid out our assumptions in table 2. In the descriptions that follow,
we refer to this table where necessary.
4.1 A conceptual model
The first step in building the conceptual model is to identify the different
parts of the system in which we are interested. In terms of a complex
system we can consider the hypertrophy of the lymph node to be the
non-linear (emergent) behaviour under investigation. The main active
component of our system is a population of homogeneous lymphocytes,
which interacts in an environment. This environment is simply the parts
of the body with which the lymphocytes interact with respect to their
migration through HEV in the lymph node.
In terms of the biology, the main cellular actors in the migration
process are the lymphocytes, high-endothelial (HE) cells and pericytes.
We consider HE cells and pericytes together in the form of a tube (a
high-endothelial venule). Lymphocytes travel through the HEVs within
the blood circulation. Outside the HEVs is the lymph node tissue, which
the lymphocytes enter if they successfully migrate through the HEV.
We have classified the different environments that the lymphocytes pass
through as states, with transitions occurring when the lymphocyte moves
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Label Assumption
1 The detail described in section 3 is correct
2 Lymphocyte migration only takes place in the HEV areas of the lymph
node
3 There is no interaction between lymphocyte agents. Lymphocytes do
not collide.
4 There are no effects from external blood circulation e.g. blood flow is
constant.
5 The volume of blood always there to accommodate size of HEV (i.e.
enough blood to fill whatever size HEV expands to).
6 Once a suitable chemokine signal has been received by a lymphocyte,
it will always migrate. Thus, subsequent stages in the adhesion cascade
(see figure 8) are deterministic.
7 Lymphocytes are essentially equivalent. They express the same levels
of receptors required for rolling and migration.
8 Lymphocyte will always re-enter blood circulation from the lymph
node. Thus, lymphocytes can only exit the system (die) in the blood
circulation state.
9 Lymphocytes are created and die at a constant rate.
10 The HEVs are homogeneous. The endothelial cells and pericytes that
make up the HEV all behave the same making the HEV appear the
same at all points.
11 Lymphocytes flow though the HEV at the same rate.
12 Lymphocytes can be captured and disassociate repeatedly whilst in the
HEV.
13 There is no change in lymphocytes that have disassociated from an
HEV wall, thus all free flowing lymphocyte are the equally likely to
capture.
14 Whilst passing through the HEV there is no change in the state of the
lymphocyte, thus there is no distinction between new and re-circulating
lymphocytes.
15 Proliferation does not occur in the lymph node.
16 The multi-stage adhesion cascade show in figure 8 can be reduced to
two probabilistic stages: capture leading to lymphocyte rolling, and
migration after receiving a chemokine activation signal.
17 The number of lymphocyte chemokine receptors does not change on
the time scale of the simulation.
18 Lymphocytes drain from the lymph node to the blood circulation at a
constant rate.
Table 2. A list of many of our modelling and simulation assumptions. Each
is given a label so that we can refer to it. This is not a complete list, but is
illustrative of the kind of assumptions we make.
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from one environment to the other. This is summarised by the state di-
agram in figure 10. The four key identified states are:
Blood Circulation: This state encompasses the parts of the body that
the lymphocyte is in when it is not in the HEV or the lymph node tissue.
It provides a place where lymphocytes can enter or leave the system. It is
the state lymphocytes will be in for most of their existence. Assumptions
4, 5, 8 and 9 apply to this state.
HEV Lumen: This state describes the lymphocyte when it is flowing
freely in the lumen of a HEV. Assumptions 10, 11, 13 and 14 apply to
this state.
Rolling: This state represents the lymphocyte when it is rolling on the
interior surface of an HEV (see figure 8). Assumptions 10 and 13 apply
to this state.
Lymph Node: This state describes the lymphocyte when it is present
in functional tissue of a lymph node. Assumptions 15 and 18 apply to
this state.
In addition to these four states, Start and Stop states provide a means
to introduce and remove a lymphocyte.
The state transitions in figure 10 map to the biology in the following
ways:
Creation A newly created lymphocyte will automatically transition into
the blood circulation state. Assumption 9 applies to this transition.
Enter HEV As a lymphocyte is transported around the body in the
blood (the blood circulation state) it will at some point enter an area of
HEV a lymph node. Assumptions 10 and 11 apply to this transition.
Exit HEV Just as a lymphocyte can enter the HEV lumen, it can also
exit the HEV lumen via the blood, transiting from the HEV lumen state
back into the blood circulation. Assumptions 10 and 11 apply to this
transition.
Capture Whilst moving freely in the HEV lumen, a lymphocyte cap-
tures onto the endothelial wall transiting to the rolling state. Assump-
tions 7, 12, 13 and 16 apply to this transition.





















Fig. 10. A generic state transition diagram for a single lymphocyte. Boxes
represent states a lymphocyte can be in and arrows represent the possible
transitions between states.
Disassociate Just as the lymphocyte can transition from flowing freely
in the lumen to rolling, it can also disassociate from rolling, moving back
to the HEV lumen. Assumptions 7, 12, 13 and 16 apply to this transition.
Migrate During the process of rolling, a lymphocyte receives a chemokine
signal from the endothelial surface of the HEV. If sufficient, this signal
produces a change in the confirmation of receptors on the lymphocyte
leading to a cascade that results in migration of the lymphocyte from
the HEV to the functional tissues of the lymph node. Assumptions 2, 6,
7 and 16 apply to this transition.
Drain After spending time in the lymph node, a lymphocyte drains in
to the lymphatic system via the efferent lymphatic vessel to rejoin the
blood circulation (see figure 6). Assumption 18 applies to this transition.
Death Whilst circulating in the blood, a lymphocyte dies. Assumptions
8 and 9 apply to this transition.
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Only the allowable transitions are shown, for example a lymphocyte in
the blood circulation state can only enter the HEV via the enter HEV
transition or cease via the death transition. In addition, as this is a
conceptual model, the eight state transitions have a meaning, but no
specific values. The values are assigned at the simulation stage, taking
the form of probabilities.
The main simplification (see Assumption 16) we make with regards
to lymphocyte rolling is to reduce the multi-stage adhesion cascade (rep-
resented in Fig. 8) down to two main steps. The first step, captured by
the capture transition, models the capture of lymphocytes on to the
endothelial wall. Once capture has occurred, the lymphocyte is in the
rolling state, waiting to be activated by a chemokine signal. The sec-
ond step, expressed by the migration transition, models the lymphocyte
receiving the chemokine signal; after this it is assumed that the lympho-
cyte succeeds in migration. Other stages in the cascade are assumed to
be either deterministic, or have such small probabilities of failing that
they are insignificant.
4.2 Simulations
A simulation is best thought of as an execution of a model (such as the
lymphocyte model in figure 10) over time. Typically time is implemented
as atomic steps, at which each element in the simulation (each lympho-
cyte) updates. Within a simulation, we need to define rules to determine
when a lymphocyte can transition between states. One way to achieve
this is to assign each transition with a probability of occurring. These
probabilities need to be extracted from the biological detail to represent
what is known to happen in the biology.
We have developed two simulations of the conceptual lymphocyte
migration model described above, which differ in the way spatial aspects
of the environment are represented. In the first, there is no explicit co-
ordinate system, only the four body locations in figure 10. Each of these
four state spaces can contain a number of lymphocyte agents, which
transit from location to location based on a set of rules. This simulation
aims to capture statistically the change in lymphocyte concentrations
in the lymph node as the probabilities on the capture and migration
transitions change.
In the second simulation, the 3-dimensional HEV tube made up of
endothelial cells, and the movement of lymphocytes through that tube,
are explicitly implemented. This supports visualisation of the HEV and
of the lymphocytes, with the HEV lumen and rolling states visually dis-
tinguishable via changes in colour. Again, the model is driven by the
















Fig. 11. Process diagram showing how lymphocyte processes (represented as
circled “L”s register with state processes (boxed)
probabilities on the transitions, but because the spatial aspect is ex-
pressed explicitly, the simulation is more obviously closer to the biology.
We refer to the two different simulations as migration-abstract and
migration-space respectively. The description in this section focuses on
the migration-abstract simulation, but draws on elements of the migration-
space simulation when necessary. Our simulations are implemented us-
ing occam-pi, a process-oriented programming (POP) language capable
of massive concurrency (for details of why we choose this approach see
[3]).
The migration-abstract simulation implements the state diagram shown
in figure 10 for a population of lymphocyte agents over a period of time.
Using the POP paradigm, each lymphocyte agent is represented as a
process which is connected via a communication channel to one of the
four body place states we are interested in (also represented as pro-
cesses): blood circulation, HEV lumen, rolling on the endothelium, and
in the functional tissue of the lymph node. The process network struc-
ture is shown in figure 11, and directly reflects the topology of the states
in figure 10. Each of the four place state processes shown has a shared
communication channel (shown as a bold arrow), to which any number
of lymphocyte processes can be connected. Each lymphocyte process is
connected to one and only one place process thus ensuring it can only
be in one state at a time. According to process-oriented design rules, the
lymphocyte processes act as clients to the server state processes.
Depending on the transition rules, a lymphocyte process can change
the state process to which it is connected, moving from one place pro-
cess to the next. Channels exist between state processes to enable this
movement, which directly reflect the allowable state transitions in fig-
ure 10. For example, in figure 12 the shaded lymphocyte process moves
from the blood circulation state to the HEV lumen state by disconnect-



















Fig. 12. Process diagram showing how lymphocytes move between state pro-
cesses
ing its communication channel from the blood circulation process and
reconnecting it to the HEV lumen process.
Every lymphocyte process updates once per time step (this is achieved
via the occam-pi barrier construct). At each step, the number of lym-
phocyte processes associated with each place process can be recorded,
to allow numerical analysis of the number lymphocytes in each state
over time. A typical simulation run necessarily contains many thou-
sands of lymphocyte processes in order to get close to the biological scale
which contains millions of lymphocytes. New lymphocyte processes can
be added during a simulation run and are automatically connected to
the blood circulation process.
The eight lymphocyte state transitions (figure 10) in the migration-
abstract simulation are each encoded a probabilistic rule. At each time
step, a lymphocyte tests for its possible for transitions. For example, a
lymphocyte in the rolling state can either disassociate to the HEV lumen
state, migrate to the lymph node state or stay in the rolling state. To
determine which of these occurs, a random number is generated for each
lymphocyte and is tested against the possible transitions. If the random
number falls in the range of a transition, then the lymphocyte will transit
into the relevant state. If not, the lymphocyte stays in its current state.
There is a mapping between probabilities and the biological detail.
To achieve an accurate simulation, we need to choose the probabilities
carefully, and try to validate to be confident that they represent what
they are supposed to. It is ongoing work to find good probabilities, the
job of which is not trivial for a number of reasons. Often the exact
biological details are poorly understood or simply not recorded. Facts can
also come from many different sources, based on different experiments
utilising different technologies and subjects. Many of these facts then
have to be combined into a single probability. Thus when constructing
these probabilities we need to document where they have come from and
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how they map to the probabilities. An example of the type of detail we
would use to construct a probability is that a quarter of lymphocytes
entering HEVs will migrate [13]. By combining this with the numbers of
lymphocytes in the body we can start to build meaning into the capture
and migration probabilities.
The following descriptions examine each transition probability and
suggests the type of biological detail we would need to generate their
values in a simulation:
Creation: The probability for creation is distinct from the other transi-
tion probabilities as it is a function of the population size rather than the
individual lymphocytes. Studies in mice show that about 1 to 2 million
T cells and B cells enter the blood circulation [16]. In a homeostatic envi-
ronment, the numbers of lymphocytes created should equal the number
that die (see death transition below).
Enter HEV, Exit HEV: Lymphocytes continually enter areas of HEV
whilst circulating in the body. The probability of a particular lympho-
cyte doing so needs to reflect an average amount of time not spent in
HEVs. It is consequently inextricably linked to the exit HEV probabil-
ity. The probability needs to encapsulate biological details such as the
relative lengths of the blood circulation system and HEVs, along with
the rates of blood flow.
Capture: In the description of the conceptual model, we discussed what
capture means and the assumptions involved. In the simulation, the cap-
ture probability relates to the biology of the receptors of lymphocytes
and endothelial cells, and the probability that the receptors on each are
close enough to interact. The interaction probability can be based on
the relative sizes of lymphocytes and the diameter of the HEV lumen
taken from the biological data. For example, a smaller lumen diameter
would increase the chances of a lymphocyte being close enough to in-
teract. Conversely, a larger diameter may relate to a larger surface area
of endothelial cell receptors to which the lymphocytes can attach, so a
larger diameter would increase the probability of capture.
Disassociate: This probability is related to the capture probability in
that it takes into account the strength of binding between lymphocytes
and the endothelial cells. A higher concentration of endothelial cell re-
ceptors should reduce this probability.
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Migrate: The migration probability is dependent on the concentration
of chemokines to induce the confirmation change in the lymphocyte
and/or the likelihood that the lymphocyte picks up the chemokine signal.
The last probability could take into account the numbers of chemokine
receptors on the lymphocyte, and the way in which endothelial cells ex-
press and present them. Assumption 17 applies.
Drain: The drain probability reflects the amount of time it takes for a
lymphocyte that has migrated into the lymph node to exit to the blood
circulation. This time can be dependent on whether the lymphocyte is
activated, but as this frequency is usually very small, we assume the rate
is constant for all lymphocytes (Assumption 18).
Death: A lymphocyte that dies will be removed from the simulation.
The probability to determine this needs to take into account the average
life of lymphocytes. In a homeostatic environment, death is compensated
by creation. Assumption 9 applies.
All probabilities need to be scaled to fit the time step of the simulation.
Each probability is also simulation specific. Our migration-space simu-
lation implements the same conceptual model as the migration-abstract
simulation, employing the same state transitions, and has a need for the
same relevant probabilities. However, the actual probability values are
subtly different. For example the capture probability in the migration-
abstract simulation incorporates the need for a lymphocyte to be near
to the endothelium for capture to occur. In the migration-space simu-
lation, the 3-dimensional space is explicit, thus the capture probability
only encapsulates the biology of receptor binding. The process of vali-
dation needs to explicitly highlight the contributions to transitions, to
make the simulations transparent and open to reasoning.
5 Verification and validation of the simulations
According to Sargent’s process, we need to validate the conceptual model
against the problem entity (and the purpose of the simulation). Ulti-
mately, we also have to argue the operational validity of the comput-
erised model (i.e. determine the behaviour has sufficient accuracy for
its intended purpose), but that is largely outside the scope of this pa-
per. As we will see, validation of the conceptual model reveals the many
gaps in both the science and the computerised model, these gaps inhibit
exploration of any research hypothesis.
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We can think of the validation process as producing an argument of
validity, in the same way that critical systems developers produce ar-
guments of safety, dependability or security. Note that just as a safety
argumentation never establishes that a system is absolutely safe (no sys-
tem is safe unless it is totally closed and inert), an argument of validity
merely states the case for validity, exposing it to critical consideration.
This is an important observation, because, in any natural complex sys-
tem, we cannot expect to provide a gold-plated guarantee of equivalence
between our conceptual model and the problem entity – indeed, if the
model contained all the complexity needed to exactly mimic the natural
system, it would be intractably large, and too complex to provide any
new research insight.
An argument is expressed as a proposition, and is reasoned on the
basis of some premises, to reach a conclusion. A variety of textual and
diagrammatic techniques allow an argument to be presented with a de-
gree of formality – exposing the premises to analysis and scrutiny (see
[17, §2.6] for a succinct review). Kelly and others [17, 35] adopt the goal
structuring notation (GSN), proposed in [37], to present arguments in-
cluding those relating to the safety or safe design of critical systems [17]
and system dependability [8], and to emphasise the role of argumentation
in design [38].
In conventional safety case argumentation, basic elements are used to
express an argument: goals (decomposable), strategies (to meeting the
goals), justifications, assumptions, contexts, and solutions. Here, our goal
is to validate the conceptual model against the problem entity. For illus-
tration, we focus on one aspect of the conceptual model, the transition
labelled Capture. This reveals many of the issues in validating a complex
system model against a natural problem entity. Whilst we do not present
a systematic analysis here, the approach could be systematised, applying
a deviational approach in the way that is common in safety work (see
[25]) and has more recently been used in security analysis (for example,
[31]).
5.1 The Capture transition and its connotations
The Capture transition takes the lymphocyte from the state HEV Lu-
men, where it is moving freely within the HEV, to the state Rolling,
where it is in the preliminary stage of the migration process. From the
Rolling state, a lymphocyte can revert to the HEV Lumen state by dis-
association, or continue its migration to the functional part of the lymph
node. We might equate Capture to the second stage shown in figure 9,
above.
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The Capture transition is an abstraction from the cell biology and
biochemistry – which has been well-researched (see the top panel of figure
9, above). However, validation of the Capture probability would require
a separate, lower-level simulation of the capture bio-chemistry (or in vivo
research). In our validation argument, the probability of capture is an
area that we must expose to external review, or to further work.
However, there are other aspects of capture that we must validate,
where the biological basis for our conceptual model is less well under-
stood. We might postulate a context for capture: the chance of a lym-
phocyte being captured depends on (a) the density of active receptors
on the endothelium; (b) the receptors on the lymphocyte; (c) the likeli-
hood of a lymphocyte being close enough to the endothelium for capture.
Thus, our simulation needs to take into account the geometry (as well
as the biochemistry) of the lymphocyte and the HEV, as well as flow
characteristics in the venule. Validation has a choice here. On one hand,
we could attempt to simulate the three-dimensional structural biology
of a HEV – capturing typical venule cell structures and their behaviour
as the HEV constricts and relaxes (an animated version of figures 5 and
7) – and analysing the flow and contact characteristics that determine
lymphocyte interaction with the endothelium chemicals. On the other
hand, we could state our assumption that the probabilities on the tran-
sition from flowing in the HEV Lumen to captured in the Rolling state
adequately captures the geometric and flow aspects of the HEV. The
first option tends to improve the biological realism (and validatability)
of the simulation, at the cost of complicating the conceptual basis of
the model. If we opt for simplicity, we must record the assumption –
which come under a general heading of environmental factors – so that
scientists appreciate the limitations of the simulation.
In the conceptual model, the transition probabilities are constant.
Each probability approximates the effect of many environmental factors,
and each factor must cause fluctuations in the rate of transition in the
short term. However, we assume that behaviour tend towards the norm
over the timescale of the simulation (or the real biology). Again, we
could postulate further research or low-level simulations to validate this
assumption: for instance, we would like to understand the effect of irreg-
ular coverage of pericytes – does this give rise to an uneven longitudinal
profile in the HEV, and if so, does this promote lymphocyte capture at
upstream locations?
This last question identifies a potential paradox in our conceptual
model: we assume constant probabilities of transition, so all lymphocyte
in the HEV Lumen state have an equal probability of being captured;
equal probability implies a homogeneous HEV environment. However,
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the hypothesis seeks to relate lymphocyte volume in the lymph node
with dilation of the HEV, so we are required to vary the cross-section
(at least) of the HEV, and it is not obvious that this is consistent with
a homogeneous HEV environment (chemically or geometrically).
As we explore the question of the HEV environment further, we dis-
cover that one possible conformation of the contracted HEV has the lin-
ing cells packed in tight folds; the folds relax as the HEV dilates. There
must, therefore, be an intermediate point at which pockets arise between
folds, which we might expect to trap lymphocytes, increasing the chance
of capture. Taking an opposing view, widening the HEV means that
lymphocytes are more able to move away from the venule walls, poten-
tially causing a fall in capture. We cannot currently validate any of the
assumptions about the geometry and flow of the HEV environment, but
we can highlight these assumptions in relation to our simulation results.
We assume that all lymphocytes are the same size – that is, there
is no differential probability across lymphocytes. This can be validated
biologically: the literature gives size ranges for lymphocytes, and we can
determine (by asking immunologists!) whether the range represents sizes
with one lymphatic system or across a species (or what): the simulation
can be driven accordingly. It is noted that much of the data taken from
the literature and used for our simulation was gathered for purposes
other than ours. We must, therefore, assume that the data is still appli-
cable in our domain.
Returning to the probability of the Capture transition, we have used
the conceptual model as the basis for two simulations. In the abstract
simulation (non-spatial), the transition probability must be used to re-
flect the effects of all factors in HEV environment and other relevant
environmental factors. However, in the spatial model, the spatial rela-
tionship between lymphocyte size and location and venule diameter and
conformance is incorporated directly – the transition probabilities ab-
stract only from the biochemistry and the surface characteristics of the
HEV.
We have not identified all assumptions of our conceptual model here.
For example, the model also abstracts from all biochemical factors: we
assume that the probability of transition expresses any underlying vari-
ability in receptor form, binding strength, mechanisms of binding and
expansion, etc. We also abstract away from the cascade details of the
rolling state and the capture, disassociation and migration transitions.
5.2 Breaking with assumptions
Validating the conceptual model against the problem domain (the biol-
ogy) can reveal inconsistencies in the biological detail and mismatches
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with our assumptions. For example, we may have based a probability
on data that has been revisited and altered by subsequent scientific re-
search; mixed data from incompatible pieces of research; used data from
fixed biological material not appropriate to the simulation. By presenting
our model and simulation assumptions, and the biological detail that has
influenced the design of our simulation, the validation process is made
easier.
If we find a problem in an assumption that breaks the model, we
need to analyse the effects and change the model accordingly. For exam-
ple, assumption 15 states that proliferation (the generation of cellular
clones) of lymphocytes does not occur in the lymph node. Based on ex-
perimentation with the simulator, we might decide that this has an effect.
Consequently we can update the conceptual model with extra states and
transitions. These changes then cascade through subsequent models to
the simulator. We need to check that changing one assumption or value
does not affect the others, and if it does then change these accordingly.
Most incorrect assumptions will not invalidate the entire model or sim-
ulation, but just require editing. Tables of assumptions and biological
details allow traceability through the modelling and simulation process.
For example a domain expert might inspect them and highlight areas of
inconsistencies leading to the model or simulation to be updated.
6 Discussion
Our conceptual model of the lymphocyte system represents a set of de-
sign decisions: we have chosen to abstract to certain (key) states of the
lymphocyte lifecycle, and we have selected probability-based transitions
as a suitable basis for experimenting with lymphocyte concentrations
and HEV dilation. The consequent validation requirements are clearly
dependent on these design decisions. Had we chosen to model at a differ-
ent level of abstraction, or to represent lymphocyte behaviour differently,
we would have different validation requirements (but a similar range of
problems relating our model to the problem entity).
Disparate levels is an inherent problem of complex systems research
and simulation. The validation proposals suggest that some of the con-
ceptual model features could be validated by either lower-level simula-
tion, or exploration of the biology (and biochemistry) at the lower level.
This idea is also inherent to the CoSMoS project – the modelling and
simulation platform that it seeks to develop has as one goal support for
multiple simulation levels. A lesson of validation might be that we need
to identify component levels, as well as component state-and-operations,
so as to facilitate validation where biological detail is uncertain.













Fig. 13. An architecture for complex system engineering, after [23]
Elsewhere, we have proposed an architecture, and some principles,
for the engineering of simulations exhibiting several layers of complex
behaviour (see [34, 32, 23]). The architecture, figure 13, for complex
systems proposes component specifications, higher-level system specifi-
cations, and a reconciliation (or linguistic integration) via strategic parts
of the common environment. Putting together these architectural ideas
with the need to identify environmental factors in determining the con-
ceptual model (and the implementation detail of the subsequent comput-
erised model), we propose an extension to Sargent’s process, as shown
in figure 14.
There is much work still be to done in the area of validating our
complex system models and simulations. This includes establishing struc-
tured ways to layout our assumptions and biological details that have
influenced our designs. We also need to establish schemes for mapping
between our biological details and simulator parameters. In addition we
are investigating structured argumentation techniques to talk about va-
lidity of complex systems simulations. Our aim is to establish patterns of
validation that are applicable to the validation of many different complex
systems.
7 Summary
We have presented a selective review of engineering approaches to engi-
neering simulations in non-complex systems and agent systems, and used






















Implementation of conceptual model
and relevant environmental features
Fig. 14. Adding environmental concerns to Sargent’s process (figure 1), to
propose a process for complex system simulation
this to initiate a case study simulation development for part of the lym-
phocyte system. The simulation is based on information from biological
literature and part of an ongoing research project in the CII.
Proposing the biological information as our problem entity, and ex-
ploration of proposed immune mechanisms as our goal, we have presented
a simple conceptual model (from which two simulations of different ab-
stractions have been created). Focusing on one part of the conceptual
model, we discuss issues relating to validation of biological research sim-
ulations.
Drawing on work in non-complex systems simulation and agent sys-
tems modelling, we have identified possible features of a process for en-
gineering complex systems simulations. The process is speculative, but
fits our experience of simulating part of the immune system.
The paper presents a first step in an engineering approach towards
scientific computer simulation; the findings are preliminary and not yet
substantiated by repetition or systematic use. However, our findings are
well grounded in wider work on critical systems engineering and assur-
ance, as well as other areas of system simulation.
From the brief exploration of validation, it is clear that arguments
of validity for research-oriented simulations of complex systems are go-
ing to be complicated, and often incomplete – the principle of exposing
assumptions to external scrutiny is an important contribution of this
paper. We expect that argumentation approaches, and deviational anal-
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ysis, will contribute to the quality and visibility of validation. In short, we
believe that the scepticism over use of computer simulation in complex
systems research can be addressed through well-established engineering
principles, just as it is being addressed in macro-scale complex systems.
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